Galcanezumab for preventing cluster headache [ID1212]
Discontinued
Reference number: GID-TA10425
Following on from information provided to NICE by the company in April 2020 the appraisal of Galcanezumab for preventing episodic cluster headache [ID1212] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.